Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

Supplemental Digital Content is available in the text.

[1]  E. Davila,et al.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. , 2020, Blood advances.

[2]  Troxel,et al.  Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. , 2020, The oncologist.

[3]  R. Advani,et al.  Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy , 2020, British journal of haematology.

[4]  H. Kohrt,et al.  Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Feldman,et al.  A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma , 2019, Blood.

[6]  Zachary L. Skidmore,et al.  Rapid Progression of Adult T-Cell Leukemia/Lymphoma as Tumor Infiltrating Treg Cells after PD-1 Blockade. , 2019, Blood.

[7]  Sonali M. Smith,et al.  Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. , 2019, Clinical lymphoma, myeloma & leukemia.

[8]  L. Obéric,et al.  Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers , 2018, American journal of hematology.

[9]  T. Waldmann,et al.  Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. , 2018, The New England journal of medicine.

[10]  R. Rad,et al.  PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis , 2017, Nature.

[11]  P. Khong,et al.  PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. , 2017, Blood.

[12]  Charles Ferté,et al.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.

[13]  M. Millenson,et al.  Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[15]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Macleod,et al.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. , 1997, Cancer research.

[17]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.